Histone deacetylase inhibitors: New hope for rheumatoid arthritis?

Current Pharmaceutical Design

Volumn 14, Issue 8, 2008, Pages 803-820

  Choo, Q Y ^a   Ho, P C ^a   Lin, H S ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Angiogenesis; Epigenetic regulation; Growth arrest; Histone deacetylase inhibitor; Nuclear factor kappa B; Osteoclastogenesis; Pro inflammatory cytokine; Rheumatoid arthritis

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; ACETYLSALICYLIC ACID; ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GOLD; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 1BETA; LEFLUNOMIDE; METHOTREXATE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PANOBINOSTAT; PHENYLBUTYRIC ACID; PIVALOYLOXYMETHYL BUTYRATE; PLATINUM; ROMIDEPSIN; SALAZOSULFAPYRIDINE; SNDX 275; TRIBUTYRIN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ATAXIA; BONE DESTRUCTION; BRAIN METASTASIS; BREAST CANCER; CARCINOGENESIS; CARTILAGE DEGENERATION; CELL CYCLE ARREST; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLITIS; COLORECTAL CANCER; CONFUSION; DEGENERATIVE DISEASE; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECG ABNORMALITY; EPIGENETICS; ESOPHAGUS CANCER; FATIGUE; FIBROBLAST; GASTROINTESTINAL SYMPTOM; GLIOMA; HEAD AND NECK CANCER; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFLAMMATORY DISEASE; INJECTION SITE REACTION; JOINT SWELLING; KAPOSI SARCOMA; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; MYELOMA; NASOPHARYNX CARCINOMA; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PARKINSON DISEASE; PATHOGENESIS; PERITONEUM CANCER; PLEURA CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; SOLID TUMOR; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; TACHYCARDIA; THROMBOCYTOPENIA; THYROID CANCER; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG DESIGN; HISTONE DEACETYLASES; HUMANS;

EID: 44449126637     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784007699     Document Type: Review

References (248)

1. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004; 350: 2591-602.
2. Lee DM, Weinblatt, ME. Rheumatoid arthritis. Lancet 2001; 358: 903-11
3. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
4. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 2: 473-88.
5. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46: 328-46.
6. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350: 2167-79.
7. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Eng J Med 2001; 344: 907-16.
8. Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: Focus on tumour necrosis factor-alpha antagoinsts. Drugs 2005; 65: 473-96.
9. Meagher EA. Cardiovascular and renovascular implications of COX-2 inhibition. Curr Pharm Des 2004; 10: 603-11.
10. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with refecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
11. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80.
12. Dogne JM, Hanson J, Supuran C, Pratico D. Coxibs and cardiovascular side-effects: From light to shadow. Curr Pharm Des 2006; 12: 971-5.
13. Lenzer J, FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. BMJ 2005; 330: 440.
14. Mount C, Featherstone J. Rheumatoid arthritis market. Nat Rev Drug Discov 2005; 4: 11-2.
15. Plosker GL, Croom KF. Sulfasalazine: A review of its use in the management of rheumatoid arthritis. Drugs 2005; 65: 1825-49.
16. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005; 65: 661-94.
17. van der Heijden JW, Dijkmans BA, Scheper RJ, Jansen G. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs - from bench to bedside. Nat Clin Pract Rheumatol 2007; 3: 26-34.
18. Klinkhoff A. Biological agents for rheumatoid arthritis: Targeting both physical function and structural damage. Drugs 2004; 64: 1267-83.
19. Cannella AC, O'Dell JR. Early rheumatoid arthritis: Pitfalls in diagnosis and review of recent clinical trials. Drugs 2006; 66: 1319-37.
20. Seymour HE, Worsley A, Smith JM, Thomas SH. Anti-TNF agents for rheumatoid arthritis. Br J Clin Pharmacol 2001; 51: 201-8.
21. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25: 84-90.
22. Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov 2007; 6: 21-2.
23. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007; 26: 1315-6.
24. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apopiosis of transformed cells. J Natl Cancer Inst 2000; 92: 1210-6.
25. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004; 91: 137-68.
26. Yoo CB, Jones PA. Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov 2006; 5: 37-50.
27. Johnstone RW. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287-99.
28. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deactylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84.
29. Piekarz RL, Robey RW, Zhan A, Kayastha G, Sayah A, Abdeldaim AH, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: Impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004; 103: 4636-43.
30. Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 2004; 10: 2289-98.
31. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005; 40: 1-13.
32. Mork C, Faller DV, Spanjaard RA. A mechanistic approach to anticancer therapy: Targeting the cell cycle with histone deacetylase inhibitors. Curr Pharm Des 2005; 11: 1091-104.
33. Blanchard F, Chipoy C. Histone deacetylase inhibitors: New drugs for the treatment of inflammatory diseases? Drug Discov Today 2005; 10: 197-204.
34. Lin HY, Chen CS, Lin SP, Weng JR, Chen CS. Targeting histone deacetylase in cancer therapy. Med Res Rev 2006; 26: 397-413.
35. Liu T, S, Kuljaca S, Tee A, Marshall GM. Fhstone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 2006; 32: 157-65
36. Inche AG, La Thangue NB. Chromatin control nnd cancer-drug discovery: realizing the promise. Drug Discov Today 2006; 11: 97-109.
37. Minucci S, Pelici PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51.
38. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5: 981-9.
39. Elaut G, Rogiers V, Vanhaecke T. The pharmaceutical potential of histone deacetylase inhibitors. Curr Pharm Des 2007; 13: 2584-620.
40. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002; 99: 2995-3000
41. Chung YL, Lee MY, Wang AJ, Yao LF. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003; 8: 707-17.
42. Mori H, Abe F, Furukawa S, Furukawa S, Sakai F, Hino M, et al. FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC) II. Biological activities in animal models. J Antibiot (Tokyo) 2003; 56: 80-6.
43. Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, Doi H, et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum 2004; 50: 3365-76.
44. Nakamura T, Kukita T, Shobuike T, Nagata K, Wu Z, Ogawa K, et al. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol 2005: 175: 5809-16.
45. Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007; 150: 862-72.
46. Joe B, Wilder RL. Animal models of rheumatoid arthritis. Mol Med Today 1999; 5: 367-9.
47. Di Sabatino A, Morera R, Ciccocioppo R, Cazzola P, Gotti S, Tinozzi FP, et al. Oral butyrate for mildly to moderately active Crohn's disease. Aliment Pharmacol Ther 2005; 22: 789-94.
48. Vernia P, Annese V, Bresci G. d'Albasio G. D'Inca R, Giaccari S, et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: Results of a multicentre trial. Eur J Clin Invest 2003; 33; 244-8.
49. Vernia P, Monteleone G, Grandinetti G, Villotti G, Di Giulio E, Frieri G, et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: Randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci 2000; 45: 976-81.
50. Steinhart AH, Brzezinski A, Baker JP. Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol 1994; 89: 179-83.
51. Luhrs H, Gerke T, Muller JG, Melcher R, Schauber J, Boxberge F, et al. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002; 37: 458-66.
52. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F, et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006; 176: 5015-22.
53. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003; 111: 539-52.
54. Garcia BA, Busby SA, Shabanowitz J, Hunt DF, Mishra N. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J Proteome Res 2005; 4: 2032-42.
55. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959-67.
56. Mishra N, Brown DR, Olorenshaw IM, Kammer GM. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci USA 2001; 98: 2628-33.
57. Reilly CM, Mishra N, Miller JM, Joshi D, Ruiz P, Richon VM, et al. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol 2004; 173: 4171-8.
58. Chen PS, Wang CC, Bortner CD, Peng GS, Wu X, Pang H, et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007; 149: 203-212.
59. Sinn DI, Kim SJ, Chu K, Jung KH, Lee ST, Song EC, et al. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol Dis 2007; 26: 464-72.
60. Numerof RP, Martin-McNulty B, Roese L, Lucas J, Su Y, Meisner R, et al. Histone deacetylase inhibitors suppress dermal inflammation in murine contact by hypersensitivity models. Exp Dermatol 2007; 16: 242-242.
61. Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT, Kim DY. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 2005; 35: 89-96.
62. Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K, et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 2005; 164: 10-21.
63. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005; 11: 1-15.
64. Iwata K, Tomita K, Sano H, Fujii Y, Yamasaki A, Shimizu E. Trichostatin A, a histone deacetylase inhibitor, down-regulates interleukin-12 transcription in SV-40-transformed lung epithelial cells. Cell Immunol 2002; 218: 26-33.
65. Adcock IM, Tsaprouni L, Bhavsar P, Ito K. Epigenetic regulation of airway inflammation. Curr Opin Immunol 2007.
66. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967-76.
67. Slevogt H, Schmeck B, Jonatat C, Zahlten J, Beermann W, van Laak V, et al. Moraxella catarrhalis induces inflammatory response of bronchial epithelial cells via MAPK and NF-kappaB activation and histone deacetylase activity reduction. Am J Physiol Lung Cell Mol Physiol 2006; 290: L818-26.
68. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004; 200: 689-95.
69. Lee KY, Ito K, Hayashi R, Jazrawi EP, Barnes PJ, Adcock IM. NF-KappaD and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription. J Immunol 2006; 176: 603-15.
70. Tsaprouni LG, Ito K, Adcock IM, Punchard N. Suppression of lipopolysaccharide- and tumour necrosis factor-alpha-induced interleukin (IL)-8 expression by glucocorticoids involves changes in IL-8 promoter acetylation. Clin Exp Immunol 2007; 150: 151-7.
71. Suuronen T, Huuskonen J, Pihlaja R, Kyrylenko S, Salminen A. Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem 2003; 87: 407-16.
72. Huuskonen J, Suuronen T, Nuutinen T, Kyrylenko S, Salminen A. Regulationof microglial inflammatory response by sodium butyrate and short-chain fatty acids. Br J Pharmacol 2004; 141: 874-80.
73. Kim HS, Whang SY, Woo MS, Park JS, Kim WK, Han IO. Sodium butyrate suppresses interferon-gamma-, but not lipopolysaccharide-mediated induction of nitric oxide and tumor necrosis factor-alpha in microglia. J Neuroimmunol 2004; 151: 85-93.
74. Huber LC, Brock M, Hemmatazad H, Giger OT, Moritz F, Trenkmann M, et al. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 2007; 56: 1087-93.
75. Lin HS, Baron R, Clement-Lacroix F. Aberrant epigenetics in rheumatoid arthritis and osteoarhritis. Future Rheumatol 2007; 2: 257-260.
76. Weidle UH, Grossmann A. Inhibition of histone deacetylases: A new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res 2000; 20: 1471-85.
77. Chambers AE, Banerjee S, Chaplin, T, Dunne J, Debernardi S, Joel SP, et al. Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer 2003; 39: 1165-75.
78. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by sbort chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 2000; 60: 4561-72.
79. Peart MJ, Smyth GK, van Laar PK, Bowtell DD, Richon VM, Marks PA, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 3697-702.
80. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: Key players in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 669-75.
81. Yamanishi Y, Firestein GS. Pathogenesis of rheumatoid arthritis: The role of synoviocytes. Rheum Dis Clin North Am 2001; 27: 355-71.
82. Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 1999; 39: 295-312.
83. Sielecki TM, Boylan JF, Benfield PA, Trainor GL. Cyclin-dependent kinase inhibitors: Useful targets in cell cycle regulation. J Med Chem 2000; 43: 1-18.
84. Rudolph J. Inhibiting transient protein-protein interactions: Lessons from the Cdc25 protein tyrosine phosphatase. Nat Rev Cancer 2007; 7: 202-11.
85. Gil J, Peters G. Regulation of The INK4b-ARF-INK4a tumour suppressor locus: All lot one or one lot all. Nat Rev Mol Cell Biol 2006; 7: 667-77.
86. Shay JW, Wright WE. Senescence and immortalization: Role of telomeres and telomerase. Carcinogenesis 2005; 26: 867-74.
87. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006; 127: 265-75.
88. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ. et al. Loss of p16Ink4a with retention of p19Arf predesposes mice to tumorigenesis. Nature 2001; 413: 86-91.
89. Krimpenfort P. Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001; 413: 83-6.
90. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S,et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 1998; 12: 2899-911.
91. Park MS, Rosai J, Nguyen HT, Capodieci P, Cordon-Cardo C, Koff A. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci USA 1999; 96: 6382-7.
92. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and femanle sterility in p27(Kip1)-deficient mice. Cell 1996; 85: 733-44.
93. Brugarolas J, Bronson RT, Jacks T. p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. J Cell Biol 1998; 141: 503-14.
94. Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001; 61: 6234-8.
95. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001; 2: 731-7.
96. Balomenos D, Martin-Caballero J, Garcia MI, Prieto I, Flores JM, Serrano M, et al. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med 2000; 6: 171-6.
97. Salvador JM, Hollander MC, Nguyen AT, Kopp JB, Barisoni L, Moore JK, et al. Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity 2002; 16: 499-508.
98. Perlman H, Bradley K, Liu H, Cole S, Shamiyeh E, Smith RC, et al. IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. J Immunol 2003; 170: 838-45.
99. Woods JM, Klosowska K, Spoden DJ, Stumbo NG, Paige DJ, Scatizzi JC, et al. A cell-cycle independent role lot p21 in regulating synovial fibroblast migration in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R113.
100. Nonomura Y, Kohsaka H, Nagasaka K, Miyasaka N. Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis. J Immunol 2003; 171: 4913-9.
101. Acharya MR, Sparreboom A, Venitz J. Figg WD. Rational development or histone deacetylase inhibitors as anticancer agents: A review. Mol Pharmacol 2005; 68: 917-32.
102. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-16.
103. Nasu K, Kohsaka H, Nonomura Y, Terada Y, Ito h, Hirokawa K, et al. Adenoviral transfer of cyclin-denendent kinase inhibitor genes suppresses collagen-induced arthritis in mice. J Immunol 2000; 165: 7246-52.
104. Taniguchi K, Kohsaka H, Inoue N, Terada Y, Ito H, Hirokawa K, et al. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med 1999; 5: 760-7.
105. Nonomura Y, Kohsaka H, Nasu K, Terada Y, Ikeda M, Miyasaka N. Suppression of arthritis by forced expression of cyclin-dependent kinase inhibitor p21(Cip1) gene into the joints. Int Immunol 2001; 13: 723-31.
106. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J 1991; 10: 4025-31.
107. Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci USA 1986; 83: 8749-53.
108. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anti-cytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996; 39: 797-809.
109. Clancy RM, Amin AR, Abramson SB. The role of nitric oxide in inflammation and immunity. Arthritis Rheum 1998; 41: 1141-51.
110. Alcaraz MJ, Guilln MI. The nitric oxide related therapeutic phenomenon: a challenging task. Curr Pharm Des 2002; 8: 215-31.
111. Miyasaka N, Hirata Y. Nitric oxide and inflammatory arthritides. Life Sci 1997; 61: 2073-81.
112. Farrell AJ, Blake DR, Palmer RM, Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 1992; 51: 1219-22.
113. Grabowski PS, England AJ, Dykhuizen R, Copland M, Benjamin N, Reid DM, et al. Elevated nitric oxide production in rheumatoid arthritis. Detection using the fasting urinary nitrate:cReatinine ratio. Arthritis Rheum 1996; 39: 643-7.
114. Onur O, Akinci AS, Akbiyik F, Unsal I. Elevated levels of nitrate in rheumatoid arthritis. Rheumatol Int 2001; 20: 154-8.
115. Ucki Y, Miyake S, Tominaga Y, Eguchi K. Increased nitric oxide levels in patients with rheumatoid arthritis. J Rheumatol 1996; 23: 230-6.
116. Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, et al. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 1995; 96: 2357-63.
117. Borderie D, Hilliquin P, Hernvann A, Kahan A, Menkes CJ, Ekindjian OG. Nitric oxide synthase is expressed in the lymphomononuclear cells of synovial fluid in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 2083-8.
118. Grabowski PS, Macpherson H, Ralston SH. Nitric oxide production in cells derived from the human joint. Br J Rheumatol 1996; 35: 207-12.
119. Melchiorri C, Meliconi R, Frizziero L, Silvestri T, Pulsatelli L, Mazzetti I, et al. Enchanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 1998; 41: 2165-74.
120. Rojas J, Paya M, Dominguez JN, Ferrandiz NL. ttCH, a selective inhibitor of inducible nitric oxide synthase expression with antiarthritic properties. Eur J Pharmacol 2003; 465: 183-9.
121. Rojas J, Paya M, Devesa I, Dominguez JN, Ferrandiz ML. Therapeutic administration of 3,4,5-trimethoxy-4′-flurochalcone, a selective inhibitor of iNOS expression, attenuates the development of adjuvant-induced arthritis in rats. Naunyn Schmiedebergs Arch Pharmacol 2003; 368: 225-33.
122. Ohtsuka M, Konno F, Honda H, Oikawa T, Ishikawa M, Iwase N, et al. PPA250 [3-(2,4-difluorophenyl)-6-[2-[4-(111-imidazol-1-ylmethyl) phenoxy]ethoxy]-2-phenylpyridine], a novel orally effective inhibitor of the dimerization of inducible nitric-oxide synthase, exhibits an anti-inflammatory effect in animal models of chronic arthritis. J Pharmacol Exp Ther 2002; 303: 52-7.
123. Fletcher DS, Widmer WR, Luell S, Christen A, Orevillo C, Shah S, et al. Therapeutic administration of a selective in hibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats. J Pharmacol Exp Ther 1998; 284: 714-21.
124. Cuzzocrea S, Chatterjee PK, Mazzon E, McDonald MC, Dugo L, Di Paola R, et al. Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis. Eur J Pharmacol 2002; 453: 119-29.
125. Connor JR, Manning PT, Settle SL, Moore WM, Jerome GM, Webber RK, et al. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric synthase. Eur J Pharmcol 1995; 273: 15-24.
126. Chakravortty D, Koide N, Kato Y, Sugiyama T, Mu MM, Yoshida T, et al. The inhibitory action of butyrate on lipopolysaccharide-induced nitric oxide production in RAW 264.7 murine macrophage cells. J Endotoxin Res 2000; 6: 243-7.
127. Yu Z, Zhang W, Kone BC. Histone deacetylases augment cvtokine induction of the iNOS gene. J Am Soc Nephrol 2002; 13: 2009-17.
128. Larsen L, Tonnesen M, Ronn SG, Storling J, Jorgensen S, Mascagni P, et al. Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia 2007; 50: 779-89.
129. Koch AE. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003; 62(Suppl 2): Ii60-7.
130. Clavel G, Bessis N, Boissier MC. Recent data on the role for angiogenesis in rheumatoid arthritis. Joint Bone Spine 2003; 70: 321-6.
131. Demasi M, Cleland LG, Cook-Johnson RJ, James MJ. Effects of hypoxia on the expression and activity of cyclooxygenase 2 in fibroblast-like synoviocytes: Interactions with monocyte-derived soluble mediators. Arthritis Rheum 2004: 50: 2441-9.
132. Stanczyk J, Ospelt C, Gay RE, Gay S. Synovial cell activation. Curr Opin Rheumatol 2006; 18: 262-7.
133. Scott BB, Zaratin PF, Gilmartin AG, Hansbury MJ, Colombo A, Belpasso C, et al. TNF-alpha modulates angiopoietin-1 expression in rheumatoid synovial fibroblasts via the NF-kappa B signalling pathway. Biochem Biophys Res Commun 2005; 328: 409-14.
134. Qian DZ, Kachhapp SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, et al. Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1 {alpha}. Cancer Res 2006; 66: 6614-21.
135. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006; 12: 634-42.
136. Zgouras D, Becker U, Loitsch S, Stein J. Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem Biophys Res Commun 2004; 316: 693-7.
137. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA. et al. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 2004; 65: 520-7.
138. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U, et al. Inhibitors of histone deacetylation downregulate the expression of endothelial nittic synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 2002; 91: 837-44.
139. Mie Lee Y, Kim SH, Kim HS, Jin Son M, Nakajima H, Jeong Kwon H, et al. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 2003; 300: 241-6.
140. Vinodhkumar R, Song YS, Ravikumar V, Ramakrishnan G, Devaki T. Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). Chem Biol Interact 2007; 165: 220-9.
141. Young DA, Lakey RL, Pennington CJ, Jones D, Kevorkian L, Edwads DR, et al. Histone deacetylase inhibitors modulate metal-loproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther 2005; 7: R503-12.
142. Rodriguez-Salvador J, Armas-Pineda C, Perezpena-Diazconti M, Chico-Ponce de Leon F, Sosa-Sainz G, Lezama P, et al. Effect of sodium butyrate on pro-matrix metalloproteinse-9 and -2 differential secretion in pediatric tumors and cell lines. J Exp Clin Cancer Res 2005; 24: 463-73.
143. Klisovic DD, Klisovic MI, Effron D, Liu S, Marcucci G, Katz SE. Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: A potential strategy for uveal melanoma. Melanoma Res 2005; 15: 147-53.
144. Kaneko F, Snito H, Saito Y, Wakabayashi K, Nakamoto N, Tada S, et al. Down-regulation oi matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate. Int J Oncol 2004; 24: 837-45.
145. Kim S H, Ahn S, Han JW, Lee HW, Lee HY, Lee YW, et al. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun 2004; 314: 964-70.
146. Liu LT, Chang HC, Chiang LC, Hung WC. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 2003; 63: 3069-72.
147. Goldring SR. Pathogenesis of bone erosions in rheumatoid athritis. Curr Opin Rheumatol 2002: 14: 406-10.
148. Rahman MM, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 2003; 101: 3451-9.
149. Kim K, Lee J, Kim JH, Jin HM, Zhou B, Lee SY, et al. Protein inhibitor of activated STAT 3 and osteoclastogenesis by Immunol 2007; 178: 5588-94.
150. Perkins ND. Integrating cell-signalling pathways with and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62.
151. Firetein GS. NF-KappaB: Holy Grail for rheumatoid Arthritis? Athritis Rheum 2004; 50: 2381-6.
152. Jeon KI, Jeong JY, Jue DM. Thiol-reactive metal Compounds inhibit NF-kappa B activation by blocking I kappa B kinase. J Immunol 2000; 164: 5984-9.
153. Imre G, Gekeler V, Leja A, Beckers T, Boehm M. Histone deacetylas inhibitors sunpress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res 2006; 66: 5409-18.
154. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasions, and abolishes osteoclastogenesis by suppressing nuclear factor-KappaB activation. J Biol Chem 2006; 281: 5612-22.
155. Hu J, Colburn NH. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res 2005; 3: 100-9.
156. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasone activity. J Biol Chem 2001; 276: 44641-6.
157. Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C. Nuclear lactor-kappaB p65 small interfering RNA or proteasome inhibitor bortezormb sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007; 6: 37-50.
158. Kim YK, Lee EK, Kang JK, Kim JA, You JS, Park JH, et al. Activation of NF-kappaB by HDAC inhibitor apicidin through Sp1-dependent de novo protein synthesis: Its implication for resistance to apoptosis. Cell Death Differ 2006; 13: 2033-41.
159. Adcock IM. Histone deacetylase inhibitors as novel anti-Inflammatory agents. Curr Opm investig Drugs 2006; 7: 966-73.
160. Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 2006; 203: 7-13.
161. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone II4 acetylation on lysines 8 and 12. Mol Cell Biol 2000; 20: 6891-903.
162. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005; 25: 552-63.
163. Egger G, Liang G, Aparicio A, Jones PA. Epegenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-63.
164. Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007; 109: 2781-90.
165. O'Connor O A. Clinical experience with the novel histone deacetylase inhibitor vorinostal (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma. Br J Cancer 2006; 95(Suppl 1): S7-S12.
166. Pauer LR, Olivares J, Cunningham C, Williams A, Grove W, Kraker A, et al. Phase I study of oral Cl-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest 2004: 22: 886-96.
167. Nemunaitis JJ, Orr D, Eager R, Cunningham CC, Williams A, Mennel R, et al. Phase I study of oral Cl-994 on combination with gemcitabine in treatment of patients with advanced cancer. Cancer J 2003; 9: 58-66.
168. Undevia SD, Kindler HL, Janisch L, Olson SC, Schilsky RL, Vogelzang NJ, et al. A phase I study of the oral combination of Cl-994 a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol 2004; 15: 1705-11.
169. Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Sui LL, et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiang agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res 2002; 8: 2142-8.
170. Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V. et al. A Phase I clinical and pharcological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 2001; 7: 3047-55.
171. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001; 7: 2292-300.
172. Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2002; 8: 963-70.
173. Gore SD, Weng LJ, Zhai S, Figg WD, Donchower RC, Dover GJ, et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia Clin Cancer Res 2001; 7: 2330-9.
174. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J
175. Duvic M, Zhang C. Clinical and laboratory experience of vorinostal (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. Br J Cancer 2006; 95(Suppl 1): S13-9.
176. Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad P, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007; 109: 2571-8.
177. Gugler R, von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1980; 5: 67-83.
178. Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drug 1994; 47: 332-72.
179. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: When is monitoring needed? Clin Pharmacokinet 2006; 45: 1061-75.
180. Barr RD, Copeland SA, Stockwell ML, Morris N, Kelton JC. Valproic acid and immune thrombocytopenia. Arch Dis Child 1982; 57: 681-4.
181. Duvic M, Talpur R, Ni X, Zhang C, Hazanka P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL). Blood 2007; 109: 31-9.
182. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006; 24: 166-73.
183. Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006; 7: 257-61.
184. Drummond DC, Noble CO, Kirpotin DR, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anti-cancer agents. Annu Rev Pharmacol Toxicol 2005; 45: 495-528
185. Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006; 12: 3997-4003.
186. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA, A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006; 5; 57-60.
187. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Nao L, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996: 93: 5705-88.
188. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds leukemia through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIF1, but independent of p53. Oncogene 1999; 18: 7016-25.
189. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cnncer cells in vitro and in vivo. Cancer Res 2000; 60: 5165-70.
190. Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int J Cancer 2002; 99: 292-8.
191. Kawamata N, Chen J, Koeffler HP. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 2007; 110: 2667-73.
192. Moody TW, Nakagawa T, Kang Y, Jakowlew S, Chan D, Jensen RT. Bombesin/ gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation. J Mol Neurosci 2006; 28: 231-8.
193. Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y, et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 1999; 42: 3001-3.
194. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of P21CIP1/WAF1 1. Cancer Res 2003; 63: 3637-45.
195. Lucass DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD, et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004; 18: 1207-14.
196. Baradari V, Huether A, Hofner M, Schuppan D, Scherulli H. Antiproliferative and proapoptotic effects of historic deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer 2006; 13: 1237-50.
197. Graham C, Tucker C, Creech J, Favours E, Billups CA, Liu T, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancel models in vivo. Clin Cancer Res 2006; 12: 223-34.
198. Hirokawa Y, Nakajima H, Hanemann CO, Kurtz A, Frahm S, Mautner V, et al. Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK226. Cancer Biol Ther 2005; 4: 379-81.
199. Ito T, Ouchida M, Morimoto Y, Yoshida A, Jitsumori Y, Ozaki T, et al. Significant growth suppression of synovial sarcomas by the histone dencetylase inhibitor FK228 in vitro and in vivo. Cancer Lett 2005; 224: 311-9.
200. Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 2002; 64: 1079-90.
201. Fournel M, Trachy-Bourget MC, Yan PT, Kalita A, Bonfils C, Beaulieu C, et al. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res 2002; 62: 4325-30.
202. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002; 62: 6108-15.
203. Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, et al. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 2007: 13: 4538-46.
204. Park JH, Jung Y, Kim TY, Kim SG, Jong HS, Lee JW, et al. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 2004; 10: 5271-81
205. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96: 4592-7.
206. Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, Zhang L, et al. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 2005; 11: 3535-42.
207. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, Rifkind RA, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001; 108: 1321-30.
208. Spiller SE, Ravanpay AC, Hahn AW, Olson JM. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neurooncol 2006; 79: 259-70.
209. Cooper AL, Greenberg VL, Lancaster PS, van Nagell JR Jr, Zimmer SG, Modesitt SC. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol Oncol 2007; 104: 596-601.
210. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc. Natl Acad Sci USA 2007; 104: 8071-6.
211. Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, et al. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 2007; 46: 1119-30.
212. Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 2007; 13: 1045-52.
213. Moradei OM, Mallais TC, Frechette S, Paquin I, Tessier PE, Leit SM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem 2007; 50: 5543-6.
214. Hamblett CL, Methot JL, Mampreian DM, Sloman DL, Stanton MG, Kral AM, et al. The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors. Bioorg Med Chem Lett 2007; 17: 5300-9.
215. Jones P, Altamura S, Chakravarty PK, Cecchetti O, De Francesco R. Gallinari P, et al. A series novel, potent, and selective histone deacetylase inhibitors. Bioorg Med Chem Lett 2006: 16: 5948-52.
216. Curtin M, Glaser K. Histone deacetylase inhibitors: The Abbott experience. Curr Med Chem 2003; 10: 2373-92.
217. Koyama Y, Tanaka Y, Saito K, Abe M, Nakatsuka K, Morimoto I, et al. Cross-linking of intercellular adhesion molecule 1 (CD54) induces AP-1 activation and IL-1beta transcription. J Immunol 1996; 157: 5097-103.
218. Miyazawa K, Mori A, Okudaira H. Establishment and characterization of a novel human rheumatoid fibroblast-like synoviocyte line, MH7A, immortalized with SV40 T antigen. J Biochem (Tokyo) 1998; 124: 1153-62.
219. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007; 16: 659-78.
220. Johnstone RW. Suberanilohydroxamic Acid. Aton Pharma. IDrugs 2004; 7: 674-82.
221. ClinicalTrials.gov. A service of the US National Institute of health. www.clinicaltrials.gov Assessed on 3 January 2008.
222. Douillard JY, Bennouna J, Vavasseur F, Deporte-Fety R, Thomare P, Giacalone F, et al. Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer. Cancer Immunol Immunother 2000; 49: 56-61.
223. Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrale (Pivanex, AN-9) in advanced non-small cell lung cancer. Luna Cancer 2004; 45: 381-6.
224. Miaer S, Reich E, Martin R, Bachem M, Altug V, Hautmann RE, et al. Tributyrin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant human prostate cancer cell lines. Int J Cancer 2000; 88: 245-51.
225. Edelman MJ, Bauer K, Khanwani S, Tait N, Trepel J, Karp J, et al. Clinical and pharmacologic study of tributyrin: An oral butyrate prodrug. Cancer Chemother Pharmacol 2003: 51: 439-44.
226. Conley BA, Egorin MJ, Tait N, Rosen DM, Sausville EA, Dover G, et al. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res 1998; 4: 629-34.
227. Kelly WK, Marks PA. Drug insight: Histone deacetylase inhibitors-development of new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005; 2: 150-7.
228. Richon VM, O'Brien JP. Histone deacetylase inhibitors: A new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 2002; 6: 662-4.
229. Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs 2007; 25: 131-8.
230. Sung MW, Waxman S. Combination ol cytotoxic-differentiation therapy with 5-flourouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res 2007; 27: 995-1001.
231. Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, et al. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study. Neyro-oncol 2005; 7: 177-82.
232. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62: 4916-21.
233. Kraker AJ, Mizzen CA, Hartl BG, Miin J, Allis CD, Merriman RL. Modulation of histone acetylation by [4-(acetylamino)-N-(2-aminophenyl) benzamide] in HCT-8 colon carcinoma. Mol Cancer Ther 2001; 2: 401-8
234. Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L, et al. Chronic oral administration of CI-994. a phase 1 study. Invest New Druas 2001; 19: 1-11.
235. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003; 307: 720-8.
236. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005; 23: 3912-22.
237. Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 2007; 121: 1138-48.
238. Nimmanapalli R. Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003; 63: 5126-35.
239. Rowinsky EK, Pacey S, Patnaik A, O'Donnell A, Mita MM, Atadja P, et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors. J Clin Oncol 2004; 22 Suppl.; 3022.
240. Ottmann OG, Deangelo DJ, Stone RM, Pfeifer H, Lowenberg B, Atadja P, et al. A phase 1, pharmacokinetic (PK and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies. J Clin Oncol 2004; 22 Suppl.: 3024.
241. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active agains human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105: 1768-76.
242. Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res 2003; 9: 5749-55.
243. Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, et al. inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res 2001; 7: 962-70.
244. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003; 2: 721-8.
245. ChromaTherapeutics. http://www-chromatherapeutics.com/CHR-3996.htm Assessed on 3 January 2008.
246. Boehrer S, Nowak D, Hoelzer D, Mitrou PS, Chow KU. Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies. Curr Pharm Des 2006; 12(1): 111-28.
247. Elaut G, Rogiers V, Vanhaecke T. The pharmaceutical potential of histone deacetylase inhibitors. Curr Pharm Des 2007: 13(25): 2584-620.
248. Kulkarni RG, Achaiah G, Sastry GN. Novel targets for antiinflammatory and antiarthritic agents. Corr Pharm Des 2006; 12(19): 2437-54.